Regorafenib mesylate

Synonyms: BAY 73-4506 mesylate
Regorafenib (BAY 73-4506) mesylate 是一种口服有效的多靶点受体酪氨酸激酶 (tyrosine kinase) 抑制剂,对 VEGFR1/2/3、PDGFRβ、Kit、RET 和 Raf-1 的 IC50 分别为 13/4.2/46、22、7、1.5 和 2.5 nM,并显示出非常强的抗肿瘤和抗血管生成活性。
产品编号: MS-W68461 CAS No.: 835621-08-4 分子式: C22H19ClF4N4O6S 分子量: 578.92
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Regorafenib (BAY 73-4506) mesylate 是一种口服有效的多靶点受体酪氨酸激酶 (tyrosine kinase) 抑制剂,对 VEGFR1/2/3、PDGFRβ、Kit、RET 和 Raf-1 的 IC50 分别为 13/4.2/46、22、7、1.5 和 2.5 nM,并显示出非常强的抗肿瘤和抗血管生成活性。

生物实验数据

生物活性 Regorafenib (BAY 73-4506) mesylate is an orally active multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR1/2/3, PDGFRβ, Kit, RET, and Raf-1 with IC50 values of 13/4.2/46, 22, 7, 1.5, and 2.5 nM, respectively, and exhibits very potent antitumor and antiangiogenic activities.
IC50 & Target Tie2:311 ± 46 nM, VEGFR1:13 ± 0.4 nM, VEGFR3:46 ± 10 nM, PDGFRβ:22 ± 3 nM, VEGFR2:4.2 ± 1.6 nM, B-Raf (V600E):19 ± 6 nM, B-Raf:28 ± 10 nM, Raf-1:2.5 ± 0.6 nM
体外研究
(In Vitro)

Regorafenib mesylate (0-10 μM, 96 h) shows anti-proliferation activity in GIST 882, Thyroid TT, MDA-MB-231, HepG2, A375 and SW620 cells.
Regorafenib mesylate (0-3000 nM, 30 min) inhibits the autophosphorylation of VEGFR2, TIE2 and PDGFR-β, and inhibits FGFR and pERK1/2.
Regorafenib mesylate causes a concentration-dependent decrease in Hep3B cell growth, with an IC50 of 5 μM. Regorafenib subsequently increases the levels of phospho-c-Jun, a JNK target, but not total c-Jun in Hep3B cells.

Cell Proliferation Assay

Cell Line: GIST 882, Thyroid TT, MDA-MB-231, HepG2, A375 and SW620 cells
Concentration: 10 μM and 5 nM
Incubation Time: 96 h
Result: Showed anti-proliferation activity in GIST 882, Thyroid TT, MDA-MB-231, HepG2, A375 and SW620 cells, with IC50 values of 45 ± 20, 34 ± 8, 401 ± 88, 560 ± 200, 900, 967 ± 287 nM. respectively.

Western Blot Analysis

Cell Line: NIH-3T3/VEGFR2 cells, (CHO)-TIE2 cells, HAoSMCs cells, MCF-7 cells
Concentration: 0, 10, 30, 100, 300, 1000, 3000 nM
Incubation Time: 30 min
Result: Inhibited the autophosphorylation of VEGFR2, TIE2 and PDGFR-β, with IC50 values of 3, 31, and 90 nM, respectively, inhibited FGFR signaling in MCF-7 breast cancer (BC) cells stimulated with FGF10, and showed inhibition of phosphorylated FGFR substrate 2 (pFRS2) and the downstream signaling kinase pERK1/2.
体内研究
(In Vivo)

Regorafenib mesylate (10 mg/kg, Orally, single dose or daily for 4 days) inhibits tumor vasculature and tumor growth in a rat GS9L glioblastoma model.
Regorafenib mesylate (0-100 mg/kg, Orally, qd × 9) exhibits antitumorigenic and antiangiogenic effects in the Colo-205, MDA-MB-231 and 786-O model.

Animal Model: Rat GS9L glioblastoma xenograft
Dosage: 10 mg/kg
Administration: Orally, single dose or daily for 4 days
Result: Inhibited tumor vasculature and tumor growth in a rat GS9L glioblastoma model.
Animal Model: Female athymic NCr nu/nu mice, Multiple xenograft models, including models derived from CRC (Colo-205), BC (MDA-MB-231) and RCC (786-O) tumors
Dosage: 0, 3, 10, 30, 100 mg/kg
Administration: Orally, qd × 9
Result: Effectively inhibited growth of the Colo-205, MDA-MB-231 and 786-O model. Significantly reduces tumor MVA, effectively inhibited the RAF/MEK/ERK signaling cascade, and drastically inhibited tumor cell proliferation.

化学信息

分子量 578.92
分子式 C22H19ClF4N4O6S
CAS No. 835621-08-4
别名 BAY 73-4506 mesylate

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础